Epizyme, Inc.
Clinical trials sponsored by Epizyme, Inc., explained in plain language.
-
Promising combo for rare sarcoma stalls as trial ends early
Disease control TerminatedThis study tested a new drug called tazemetostat combined with standard chemotherapy (doxorubicin) for people with advanced epithelioid sarcoma, a rare cancer of connective tissues. The goal was to see if the combination was safe and could help people live longer without their ca…
Phase: PHASE1 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated May 17, 2026 05:06 UTC
-
Promising combo for resistant prostate cancer falls short
Disease control TerminatedThis study tested a new drug, tazemetostat, combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in men with advanced prostate cancer that no longer responds to hormone treatment. The goal was to see if the combination was safe and could delay cancer …
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Liver Function's impact on cancer drug tazemetostat under microscope
Knowledge-focused TerminatedThis study looked at how the drug tazemetostat is processed in the body of people with advanced cancer who also have moderate or severe liver problems. It compared their blood drug levels to those with normal liver function. The goal was to understand safety and dosing, but the s…
Phase: PHASE1 • Sponsor: Epizyme, Inc. • Aim: Knowledge-focused
Last updated May 17, 2026 05:04 UTC